PharmEasy-owned diagnostics player posts strong YoY profit and margin expansion, despite QoQ slowdown and radiology drag.
PharmEasy-owned Thyrocare reported a 48.1% YoY jump in consolidated net profit to INR 28.1 Cr in Q3 FY26, riding on robust pathology volumes and improved margins. However, profits fell 41.4% sequentially from INR 47.8 Cr, reflecting seasonal softness and one-time costs.
Revenue and Profit Snapshot
- Revenue from operations rose 17.8% YoY to INR 195.5 Cr, but dropped 9.7% QoQ from INR 216.5 Cr.
- Total income, including INR 5 Cr in other income, reached INR 200.5 Cr.
- Total expenses increased 12.2% YoY to INR 159.2 Cr, driven partly by exceptional costs of INR 5.9 Cr related to wage code adjustments and bonuses.
Margin and EBITDA Performance
Thyrocare reported a 38% YoY rise in EBITDA to INR 57.6 Cr, while normalised EBITDA—excluding non-cash ESOP charges from parent API Holdings—grew 26% to INR 62.2 Cr.
- Reported EBITDA margin rose to 29% from 25% last year.
- Normalised margin hit 32%, up from 30%, aided by:
- Higher pathology volumes
- Improved gross margins, up 300 bps YoY to 76%
- Operating leverage gains
So, why the profit dip QoQ? Seasonality and the one-time labour costs skewed the comparison.
Pathology Drives, Radiology Lags
Pathology continued to anchor growth:
- Revenue rose 20% YoY
- Tests processed: 4.96 Cr, up 22% YoY
- Patients served: 45 Lakh, up 14%
- Active franchisees: 10,300, up 12%
In contrast, radiology revenue declined 7% YoY, hit by weak performance at Pulse Hitech and a strategic pullback from low-margin centres.
- Franchisee pathology revenue: INR 112.2 Cr, up 12% YoY
- Partnership revenue: INR 60.1 Cr, up 39% YoY
The franchisee growth rate moderated, mainly due to tighter credit controls in the Vimta Diagnostics business.
Operational Highlights & Expansion
- Complaint rate fell 43% YoY to 3.2 per million tests, with 97% of samples processed in NABL-accredited labs.
- Thyrocare now operates 39 labs in India and one in Tanzania, which is fully consolidated.
New labs were launched in Davangere (Karnataka) and Mandi (Himachal Pradesh) in Q3.
What’s Next?
Looking ahead, Thyrocare is doubling down on its pathology-first strategy with plans to:
- Expand its franchise network
- Deepen partnerships with insurers and at-home diagnostic platforms
- Scale operations in Tanzania
- Limit exposure to lower-margin radiology services
Is this a sign that diagnostics players are returning to disciplined, margin-led growth after pandemic-fueled volatility?
TL;DR
Thyrocare’s Q3 FY26 profit rose 48% YoY to INR 28.1 Cr on strong pathology volumes and better margins. Revenue grew 17.8%, but dipped QoQ. Radiology drag and one-time costs pulled profits sequentially. The firm is scaling its franchise and B2B partnerships while expanding abroad.
AI summary
- Q3 profit up 48% YoY to INR 28.1 Cr; down QoQ
- Revenue rose 17.8% YoY; pathology led growth
- EBITDA margin improved to 29%; normalised at 32%
- Franchise and partnership revenues saw double-digit growth
- Company expanding lab network, focusing on core pathology
